Bridging the GLP-1 Care Gap for Better Outcomes and ROI

  • Webinar
  • GLP-1s

While GLP-1 medications have shown much promise for weight loss, they can leave people in worse health than before, especially when medications are not used according to the drug label: as an adjunct to a diet and exercise program. 

Yet, our healthcare system isn’t well-equipped to support patients during and after a GLP-1 course of care. Primary care clinicians, who typically have little training in obesity, are getting inundated with patients’ requests for GLP-1s, but they generally lack the time to manage and support patients’ use of the drugs over months—hence fueling the GLP-1 care gap. 

Without the right support system, patients risk losing a significant amount of muscle mass, strength, and bone density, which can result in a lowered resting metabolic rate, worsening insulin resistance, and weight regain after stopping the medication. The impact? Poor health outcomes for patients and exacerbated costs for payers.

Join our expert panel as we delve into:

  • The science behind GLP-1s and muscle loss
  • Why GLP-1 success, from both an outcomes and cost savings perspective, depends on tailored behavior change
  • How Noom’s GLP-1 Companion can help close the care gap for your GLP-1 population

Speakers

  • Dr Linda Anegawa, MD

    Chief Medicine Officer

  • Alexander Fabry

    VP of Healthcare Product
    Noom

Watch On-Demand Webinar

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Related Content

  • Blog
  • GLP-1s
  • May 10
  • 1 min read

Employer Strategies for Maximizing the Promise of GLP-1s

The numbers are clear: 160 million adults in the U.S. want to improve their health and well-being through weight loss. As many employers already know, adding obesity management programs to health benefit plans can boost employee motivation and health outcomes. For those who are affected, reducing weight by just 5-10% can improve risk factors and […]

By Noom Team
Mind the GLP-1 Care Gap
  • White Paper
  • Noom for Work
  • May 10
  • 1 min read

Mind the GLP-1 Care Gap

The obesity epidemic in America is causing chronic conditions like type 2 diabetes, heart disease, and hypertension to rise at an alarming rate, putting significant strain on healthcare systems. While GLP-1 medications have shown impressive clinical results in treating obesity, in order for them to be effective, they must be combined with lifestyle changes. Noom’s […]

By Noom Team
  • Blog
  • May 10
  • 1 min read

From Weight Loss to Risk: Understanding GLP-1’s Impact on Eating Disorders

Weight loss medication abuse is not new. Diet pills, caffeine, laxatives, and others have been around for a long time, but with the emergence of GLP-1s, more reports of disordered eating have surfaced. While these drugs have helped millions of individuals reach their weight loss goals, many suffer side effects that ultimately lead them to discontinue use, resulting not only in money lost, but weight regain. In this post, we'll deep dive into the discussion around GLP-1s and eating disorders, to ensure that employers, providers and health plans have access to the right support for members on GLP-1s.

By Noom Team

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.

REQUEST DEMO